Open access
Aug 2026
Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study
Inebilizumab demonstrated real‐world effectiveness and a manageable safety profile in a diverse population of patients with AQP4‐IgG‐seropositive NMOSD, supporting the findings of the pivotal N‐MOmentum trial.
Meng-Cui Gui, Jiayang Zhan, Wei Li et al.
· Annals of Clinical and Trans... · 0 citations